Genes and Pathology of Non-Small Cell Lung Carcinoma

Seminars in Oncology

Volumn 41, Issue 1, 2014, Pages 28-39

  Sakashita, Shingo ^a   Sakashita, Mai ^a   Sound Tsao, Ming ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PATHOLOGY, CLINICAL; PRACTICE GUIDELINES AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84894438482     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.12.008     Document Type: Article

References (111)

1. W.D. Travis, E. Brambilla, M. Noguchi, A.G. Nicholson, K.R. Geisinger, and Y. Yatabe et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
2. N.I. Lindeman, P.T. Cagle, M.B. Beasley, D.A. Chitale, S. Dacic, and G. Giaccone et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology J Thorac Oncol 8 7 2013 823 859
3. N.I. Lindeman, P.T. Cagle, M.B. Beasley, D.A. Chitale, S. Dacic, and G. Giaccone et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology J Mol Diagn 15 4 2013 415 453
4. N.I. Lindeman, P.T. Cagle, M.B. Beasley, D.A. Chitale, S. Dacic, and G. Giaccone et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Arch Pathol Lab Med 137 2013 828 860
5. W.D. Travis, E. Brambilla, H. Mullere-Hermelink, C.C. Harris World Health Organization classification of tumours Pathology and fenetics of tumours of the lung, pleura, thymus and heart 2004 IARC Press Lyon
6. D.H. Johnson, L. Fehrenbacher, W.F. Novotny, R.S. Herbst, J.J. Nemunaitis, and D.M. Jablons et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2004 2184 2191
7. G. Scagliotti, T. Brodowicz, F.A. Shepherd, C. Zielinski, J. Vansteenkiste, and C. Manegold et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer J Thorac Oncol 6 2011 64 70
8. S.H. Ou, and J.A. Zell Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies J Thorac Oncol 4 2009 1202 1211
9. C.M. Sagerup, M. Smastuen, T.B. Johannesen, A. Helland, and O.T. Brustugun Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients J Thorac Oncol 7 2012 57 63
10. R. Yesner, B. Gerstl, and O. Auerbach Application of the World Health Organization classification of lung carcinoma to biopsy material Ann Thorac Surg 10 1965 33 49
11. J.E. Grilley-Olson, D.N. Hayes, D.T. Moore, K.O. Leslie, M.D. Wilkerson, and B.F. Qaqish et al. Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets Arch Pathol Lab Med 137 2013 32 40
12. A.G. Nicholson, L.J. Perry, P.M. Cury, P. Jackson, C.M. McCormick, and B. Corrin et al. Reproducibility of the WHO/IASLC grading system for pre-invasive squamous lesions of the bronchus: a study of inter-observer and intra-observer variation Histopathology 38 2001 202 208
13. M. Noguchi, A. Morikawa, M. Kawasaki, Y. Matsuno, T. Yamada, and S. Hirohashi et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis Cancer 75 1995 2844 2852
14. A. Yoshizawa, N. Motoi, G.J. Riely, C.S. Sima, W.L. Gerald, and M.G. Kris et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases Mod Pathol 24 2011 653 664
15. A.C. Borczuk, F. Qian, A. Kazeros, J. Eleazar, A. Assaad, and J.R. Sonett et al. Invasive size is an independent predictor of survival in pulmonary adenocarcinoma Am J Surg Pathol 33 2009 462 469
16. J. Yim, L.C. Zhu, L. Chiriboga, H.N. Watson, J.D. Goldberg, and A.L. Moreira Histologic features are important prognostic indicators in early stages lung adenocarcinomas Mod Pathol 20 2007 233 241
17. D.H. Garfield, J. Cadranel, and H.L. West Bronchioloalveolar carcinoma: the case for two diseases Clin Lung Cancer 9 2008 24 29
18. A. Hata, N. Katakami, S. Fujita, R. Kaji, Y. Imai, and Y. Takahashi et al. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma J Thorac Oncol 5 2010 1197 1200
19. E. Sawada, A. Nambu, U. Motosugi, T. Araki, S. Kato, and Y. Sato et al. Localized mucinous bronchioloalveolar carcinoma of the lung: thin-section computed tomography and fluorodeoxyglucose positron emission tomography findings Jpn J Radiol 28 2010 251 258
20. H.Y. Lee, K.S. Lee, J. Han, B.T. Kim, Y.S. Cho, and Y.M. Shim et al. Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons Lung Cancer 65 2009 170 175
21. K.E. Finberg, L.V. Sequist, V.A. Joshi, A. Muzikansky, J.M. Miller, and M. Han et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features J Mol Diagn 9 2007 320 326
22. N.S. Goldstein, and M. Thomas Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies Am J Clin Pathol 116 2001 319 325
23. M. Wislez, M. Antoine, L. Baudrin, V. Poulot, A. Neuville, and M. Pradere et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib Lung cancer 68 2010 185 191
24. W.D. Travis, E. Brambilla, M. Noguchi, A. Nicholson, K. Geisinger, and Y. Yatabe et al. Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification Arch Pathol Lab Med 137 5 2012 685 705
25. E. Thunnissen, M.B. Beasley, A.C. Borczuk, E. Brambilla, L.R. Chirieac, and S. Dacic et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study Mod Pathol 25 2012 1574 1583
26. A. Warth, T. Muley, M. Meister, A. Stenzinger, M. Thomas, and P. Schirmacher et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival J Clin Oncol 30 2012 1438 1446
27. W. Sterlacci, S. Savic, T. Schmid, W. Oberaigner, J. Auberger, and M. Fiegl et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact Am J Clin Pathol 137 2012 946 956
28. R. Ocque, N. Tochigi, N.P. Ohori, and S. Dacic Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens Am J Clin Pathol 136 2011 81 87
29. P.S. Loo, S.C. Thomas, M.C. Nicolson, M.N. Fyfe, and K.M. Kerr Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens J Thorac Oncol 5 2010 442 447
30. J. Terry, S. Leung, J. Laskin, K.O. Leslie, A.M. Gown, and D.N. Ionescu Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples Am J Surg Pathol 34 2010 1805 1811
31. N. Rekhtman, D.C. Ang, C.S. Sima, W.D. Travis, and A.L. Moreira Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens Mod Pathol 24 2011 1348 1359
32. J.A. Bishop, J. Teruya-Feldstein, W.H. Westra, G. Pelosi, W.D. Travis, and N. Rekhtman p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma Mod Pathol 25 2012 405 415
33. D. Nonaka A study of DeltaNp63 expression in lung non-small cell carcinomas Am J Surg Pathol 36 2012 895 899
34. I.B. Weinstein, and A. Joe Oncogene addiction Cancer Res 68 2008 3077 3080
35. I.B. Weinstein Cancer. Addiction to oncogenes - the Achilles heal of cancer Science 297 2002 63 64
36. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
37. S.V. Sharma, D.W. Bell, J. Settleman, and D.A. Haber Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
38. M. Soda, Y.L. Choi, M. Enomoto, S. Takada, Y. Yamashita, and S. Ishikawa et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
39. K. Rikova, A. Guo, Q. Zeng, A. Possemato, J. Yu, and H. Haack et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 2007 1190 1203
40. K. Bergethon, A.T. Shaw, S.H. Ou, R. Katayama, C.M. Lovly, and N.T. McDonald et al. ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 2012 863 870
41. K. Takeuchi, M. Soda, Y. Togashi, R. Suzuki, S. Sakata, and S. Hatano et al. RET, ROS1 and ALK fusions in lung cancer Nat Med 18 2012 378 381
42. K.M. Kerr Personalized medicine for lung cancer: new challenges for pathology Histopathology 60 2012 531 546
43. L. Ding, G. Getz, D.A. Wheeler, E.R. Mardis, M.D. McLellan, and K. Cibulskis et al. Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069 1075
44. B.A. Weir, M.S. Woo, G. Getz, S. Perner, L. Ding, and R. Beroukhim et al. Characterizing the cancer genome in lung adenocarcinoma Nature 450 2007 893 898
45. B. Job, A. Bernheim, M. Beau-Faller, S. Camilleri-Broet, P. Girard, and P. Hofman et al. Genomic aberrations in lung adenocarcinoma in never smokers PloS One 5 2010 e15145
46. J.S. Seo, Y.S. Ju, W.C. Lee, J.Y. Shin, J.K. Lee, and T. Bleazard et al. The transcriptional landscape and mutational profile of lung adenocarcinoma Genome Res 22 2012 2109 2119
47. M. Imielinski, A.H. Berger, P.S. Hammerman, B. Hernandez, T.J. Pugh, and E. Hodis et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 150 2012 1107 1120
48. R. Govindan, L. Ding, M. Griffith, J. Subramanian, N.D. Dees, and K.L. Kanchi et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers Cell 150 2012 1121 1134
49. T. Kohno, H. Ichikawa, Y. Totoki, K. Yasuda, M. Hiramoto, and T. Nammo et al. KIF5B-RET fusions in lung adenocarcinoma Nat Med 18 2012 375 377
50. D. Lipson, M. Capelletti, R. Yelensky, G. Otto, A. Parker, and M. Jarosz et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies Nat Med 18 2012 382 384
51. S.C. Kim, Y. Jung, J. Park, S. Cho, C. Seo, and J. Kim et al. A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers PloS One 8 2013 e55596
52. P.P. Massion, W.L. Kuo, D. Stokoe, A.B. Olshen, P.A. Treseler, and K. Chin et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway Cancer Res 62 2002 3636 3640
53. C. Garnis, W.W. Lockwood, E. Vucic, Y. Ge, L. Girard, and J.D. Minna et al. High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. International journal of cancer J Int Cancer 118 2006 1556 1564
54. C. Garnis, J.J. Davies, T.P. Buys, M.S. Tsao, C. MacAulay, and S. Lam et al. Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression Oncogene 24 2005 4806 4812
55. M.C. Boelens, K. Kok, P. van der Vlies, G. van der Vries, H. Sietsma, and W. Timens et al. Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis Lung Cancer 66 2009 372 378
56. A.J. Bass, H. Watanabe, C.H. Mermel, S. Yu, S. Perner, and R.G. Verhaak et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas Nat Genet 41 2009 1238 1242
57. K.J. Craddock, W.L. Lam, and M.S. Tsao Applications of array-CGH for lung cancer Methods Mol Biol 973 2013 297 324
58. T. Hussenet, S. Dali, J. Exinger, B. Monga, B. Jost, and D. Dembele et al. SOX2 is an oncogene activated by recurrent 3q26. 3 amplifications in human lung squamous cell carcinomas PloS One 5 2010 e8960
59. J. Weiss, M.L. Sos, D. Seidel, M. Peifer, T. Zander, and J.M. Heuckmann et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer Sci Translat Med 2 2010 62ra93
60. Z. Kan, B.S. Jaiswal, J. Stinson, V. Janakiraman, D. Bhatt, and H.M. Stern et al. Diverse somatic mutation patterns and pathway alterations in human cancers Nature 466 2010 869 873
61. Cancer Genome Atlas Research Network, Hammerman PS, Lawrence MS, Voet D, Jing R, Cibulskis K, et al. Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 525
62. N.J. Wang, Z. Sanborn, K.L. Arnett, L.J. Bayston, W. Liao, and C.M. Proby et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma Proc Natl Acad Sci U S A 108 2011 17761 17766
63. J. Voortman, J.H. Lee, J.K. Killian, M. Suuriniemi, Y. Wang, and M. Lucchi et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors Proc Natl Acad Sci U S A 107 2010 13040 13045
64. M. Peifer, L. Fernandez-Cuesta, M.L. Sos, J. George, D. Seidel, and L.H. Kasper et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer Nat Genet 44 2012 1104 1110
65. M.L. Sos, F. Dietlein, M. Peifer, J. Schottle, H. Balke-Want, and C. Muller et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer Proc Natl Acad Sci U S A 109 2012 17034 17039
66. C.M. Rudin, S. Durinck, E.W. Stawiski, J.T. Poirier, Z. Modrusan, and D.S. Shames et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer Nat Genet 44 2012 1111 1116
67. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
68. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
69. W. Pao, T.Y. Wang, G.J. Riely, V.A. Miller, Q. Pan, and M. Ladanyi et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
70. G.J. Riely, K.A. Politi, V.A. Miller, and W. Pao Update on epidermal growth factor receptor mutations in non-small cell lung cancer Clin Cancer Res 12 2006 7232 7241
71. W. Zhou, D. Ercan, P.A. Janne, and N.S. Gray Discovery of selective irreversible inhibitors for EGFR-T790M Bioorganic Med Chem Lett 21 2011 638 643
72. W. Pao, and N. Girard New driver mutations in non-small-cell lung cancer Lancet Oncol 12 2011 175 180
73. R. Penzel, C. Sers, Y. Chen, U. Lehmann-Muhlenhoff, S. Merkelbach-Bruse, and A. Jung et al. EGFR mutation detection in NSCLC - assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC Virchows Arch 458 2011 95 98
74. H. Yasuda, S. Kobayashi, and D.B. Costa EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications Lancet Oncol 13 2012 e23-31
75. K. Ohashi, Y.E. Maruvka, F. Michor, and W. Pao Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease J Clin Oncol 31 2013 1070 1080
76. A.F. Gazdar Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 28 Suppl 1 2009 S24-31
77. R. Chiarle, C. Voena, C. Ambrogio, R. Piva, and G. Inghirami The anaplastic lymphoma kinase in the pathogenesis of cancer Nat Rev Cancer 8 2008 11 23
78. M.P. Martelli, G. Sozzi, L. Hernandez, V. Pettirossi, A. Navarro, and D. Conte et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues Am J Pathol 174 2009 661 670
79. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson, S.R. Digumarthy, D.B. Costa, and R.S. Heist et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
80. L. Horn, and A. Sandler Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer Clin Cancer Res 15 2009 5040 5048
81. K. Takeuchi, Y.L. Choi, Y. Togashi, M. Soda, S. Hatano, and K. Inamura et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry- based diagnostic system for ALK-positive lung cancer Clin Cancer Res 15 2009 3143 3149
82. X. Zhang, S. Zhang, X. Yang, J. Yang, Q. Zhou, and L. Yin et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression Mol Cancer 9 2010 188
83. J.H. Paik, G. Choe, H. Kim, J.Y. Choe, H.J. Lee, and C.T. Lee et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization J Thorac Oncol 6 2011 466 472
84. E.S. Yi, J.M. Boland, J.J. Maleszewski, A.C. Roden, A.M. Oliveira, and M.C. Aubry et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH J Thorac Oncol 6 2011 459 465
85. S.J. Rodig, M. Mino-Kenudson, S. Dacic, B.Y. Yeap, A. Shaw, and J.A. Barletta et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population Clin Cancer Res 15 2009 5216 5223
86. L.M. Sholl, S. Weremowicz, S.W. Gray, K.K. Wong, L.R. Chirieac, and N.I. Lindeman et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas J Thorac Oncol 8 2013 322 328
87. Y.G. Zhang, M.L. Jin, L. Li, H.Y. Zhao, X. Zeng, and L. Jiang et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT-PCR on paraffin-embedded tissues PloS One 8 2013 e64821
88. J.M. Sun, Y.L. Choi, J.K. Won, F.R. Hirsch, J.S. Ahn, and M.J. Ahn et al. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK J Thorac Oncol 7 2012 e36 e38
89. C. Li, R. Fang, Y. Sun, X. Han, F. Li, and B. Gao et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers PloS One 6 2011 e28204
90. V.M. Rimkunas, K.E. Crosby, D. Li, Y. Hu, M.E. Kelly, and T.L. Gu et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion Clin Cancer Res 18 2012 4449 4457
91. A. Charest, K. Lane, K. McMahon, J. Park, E. Preisinger, and H. Conroy et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) Genes Chromosomes Cancer 37 2003 58 71
92. H.J. Jun, H. Johnson, R.T. Bronson, S. de Feraudy, F. White, A. Charest The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation Cancer Res 72 2012 3764 3774
93. Y. Suehara, M. Arcila, L. Wang, A. Hasanovic, D. Ang, and T. Ito et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions Clin Cancer Res 18 2012 6599 6608
94. M.A. Davies, P.S. Fox, N.E. Papadopoulos, A.Y. Bedikian, W.J. Hwu, and A.J. Lazar et al. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma Clin Cancer Res 18 2012 1120 1128
95. Y. Arai, Y. Totoki, H. Takahashi, H. Nakamura, N. Hama, and T. Kohno et al. Mouse model for ROS1-rearranged lung cancer PloS One 8 2013 e56010
96. M. Stumpfova, and P.A. Janne Zeroing in on ROS1 rearrangements in non-small cell lung cancer Clin Cancer Res 18 2012 4222 4224
97. K.D. Davies, A.T. Le, M.F. Theodoro, M.C. Skokan, D.L. Aisner, and E.M. Berge et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer Clin Cancer Res 18 2012 4570 4579
98. A. Yoshida, T. Kohno, K. Tsuta, S. Wakai, Y. Arai, and Y. Shimada et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases Am J Surg Pathol 37 2013 554 562
99. E.G. Shaw, M. Wang, S.W. Coons, D.G. Brachman, J.C. Buckner, and K.J. Stelzer et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802 J Clin Oncol 30 2012 3065 3070
100. M.M. Awad, R. Katayama, M. McTigue, W. Liu, Y.L. Deng, and A. Brooun et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1 N Engl J Med 368 25 2013 2395 2401
101. E.M. Haugsten, A. Wiedlocha, S. Olsnes, and J. Wesche Roles of fibroblast growth factor receptors in carcinogenesis Mol Cancer Res 8 2010 1439 1452
102. V.D. Acevedo, M. Ittmann, and D.M. Spencer Paths of FGFR-driven tumorigenesis Cell Cycle 8 2009 580 588
103. L.H. Kohler, M. Mireskandari, T. Knosel, A. Altendorf-Hofmann, A. Kunze, and A. Schmidt et al. FGFR1 expression and gene copy numbers in human lung cancer Virchows Arch 461 2012 49 57
104. D.J. Jonker, L.S. Rosen, M.B. Sawyer, F. de Braud, G. Wilding, and C.J. Sweeney et al. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors Ann Oncol 22 2011 1413 1419
105. A.N. Brooks, E. Kilgour, and P.D. Smith Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer Clin Cancer Res 18 2012 1855 1862
106. N. Rekhtman, P.K. Paik, M.E. Arcila, L.J. Tafe, G.R. Oxnard, and A.L. Moreira et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations Clin Cancer Res 18 2012 1167 1176
107. K. Okudela, M. Suzuki, S. Kageyama, T. Bunai, K. Nagura, and H. Igarashi et al. PIK3CA mutation and amplification in human lung cancer Pathol Int 57 2007 664 671
108. M. Ji, H. Guan, C. Gao, B. Shi, and P. Hou Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC) BMC Cancer 11 2011 147
109. H. Yamamoto, H. Shigematsu, M. Nomura, W.W. Lockwood, M. Sato, and N. Okumura et al. PIK3CA mutations and copy number gains in human lung cancers Cancer Res 68 2008 6913 6921
110. O. Kawano, H. Sasaki, K. Endo, E. Suzuki, H. Haneda, and H. Yukiue et al. PIK3CA mutation status in Japanese lung cancer patients Lung Cancer 54 2006 209 215
111. J.E. Chaft, M.E. Arcila, P.K. Paik, C. Lau, G.J. Riely, and M.C. Pietanza et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling Mol Cancer Therapeut 11 2012 485 491